351 related articles for article (PubMed ID: 27196490)
41. Feasibility of Laparoscopic Total Mesorectal Excision with Extended Lateral Pelvic Lymph Node Dissection for Advanced Lower Rectal Cancer after Preoperative Chemoradiotherapy.
Ogura A; Akiyoshi T; Nagasaki T; Konishi T; Fujimoto Y; Nagayama S; Fukunaga Y; Ueno M; Kuroyanagi H
World J Surg; 2017 Mar; 41(3):868-875. PubMed ID: 27730352
[TBL] [Abstract][Full Text] [Related]
42. Systemic Chemotherapy as Salvage Treatment for Locally Advanced Rectal Cancer Patients Who Fail to Respond to Standard Neoadjuvant Chemoradiotherapy.
Sclafani F; Brown G; Cunningham D; Rao S; Tekkis P; Tait D; Morano F; Baratelli C; Kalaitzaki E; Rasheed S; Watkins D; Starling N; Wotherspoon A; Chau I
Oncologist; 2017 Jun; 22(6):728-736. PubMed ID: 28476941
[TBL] [Abstract][Full Text] [Related]
43. Long-term outcome of patients with complete pathologic response after neoadjuvant chemoradiation for cT3 rectal cancer: implications for local excision surgical strategies.
Belluco C; De Paoli A; Canzonieri V; Sigon R; Fornasarig M; Buonadonna A; Boz G; Innocente R; Perin T; Cossaro M; Polesel J; De Marchi F
Ann Surg Oncol; 2011 Dec; 18(13):3686-93. PubMed ID: 21691880
[TBL] [Abstract][Full Text] [Related]
44. Routine defunctioning stoma after chemoradiation and total mesorectal excision: a single-surgeon experience.
Lin SC; Chen PC; Lee CT; Tsai HM; Lin PC; Chen HH; Wu YH; Lin BW; Su WP; Lee JC
World J Gastroenterol; 2013 Mar; 19(11):1797-804. PubMed ID: 23555168
[TBL] [Abstract][Full Text] [Related]
45. Individualizing surgical treatment based on tumour response following neoadjuvant therapy in T4 primary rectal cancer.
Denost Q; Kontovounisios C; Rasheed S; Chevalier R; Brasio R; Capdepont M; Rullier E; Tekkis PP
Eur J Surg Oncol; 2017 Jan; 43(1):92-99. PubMed ID: 27717529
[TBL] [Abstract][Full Text] [Related]
46. The impact of robotic total mesorectal excision on survival of patients with rectal cancer-a propensity matched analysis.
Tejedor P; Sagias F; Flashman K; Lee YH; Naqvi S; Kandala N; Khan J
Int J Colorectal Dis; 2019 Dec; 34(12):2081-2089. PubMed ID: 31712874
[TBL] [Abstract][Full Text] [Related]
47. YpN0 rectal cancer patients with sterilized lymph nodes after neoadjuvant chemoradiotherapy are of greater risk of recurrence.
Manceau G; Margot N; Augustin J; Bardier A; Simon JM; Bachet JB; Spano JP; Maingon P; Vaillant JC; Karoui M
Dig Liver Dis; 2020 Feb; 52(2):214-220. PubMed ID: 31427089
[TBL] [Abstract][Full Text] [Related]
48. Comparative outcome between chemoradiotherapy and lateral pelvic lymph node dissection following total mesorectal excision in rectal cancer.
Kim JC; Takahashi K; Yu CS; Kim HC; Kim TW; Ryu MH; Kim JH; Mori T
Ann Surg; 2007 Nov; 246(5):754-62. PubMed ID: 17968166
[TBL] [Abstract][Full Text] [Related]
49. Tumor response and negative distal resection margins of rectal cancer after hyperthermochemoradiation therapy.
Tsutsumi S; Tabe Y; Fujii T; Yamaguchi S; Suto T; Yajima R; Morita H; Kato T; Shioya M; Saito J; Asao T; Nakano T; Kuwano H
Anticancer Res; 2011 Nov; 31(11):3963-7. PubMed ID: 22110227
[TBL] [Abstract][Full Text] [Related]
50. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial.
Rullier E; Vendrely V; Asselineau J; Rouanet P; Tuech JJ; Valverde A; de Chaisemartin C; Rivoire M; Trilling B; Jafari M; Portier G; Meunier B; Sieleznieff I; Bertrand M; Marchal F; Dubois A; Pocard M; Rullier A; Smith D; Frulio N; Frison E; Denost Q
Lancet Gastroenterol Hepatol; 2020 May; 5(5):465-474. PubMed ID: 32043980
[TBL] [Abstract][Full Text] [Related]
51. [Evaluation of progression-free survival for locally advanced rectal cancer by MRI after neoadjuvant chemoradiotherapy and total mesorectal excision].
Zhang JX; Yang Z; Fan P; Zhang JJ; Xin L; Hou LN; Du XS; Yang XT
Zhonghua Zhong Liu Za Zhi; 2018 Feb; 40(2):121-126. PubMed ID: 29502372
[No Abstract] [Full Text] [Related]
52. Stage-to-stage comparison of preoperative and postoperative chemoradiotherapy for T3 mid or distal rectal cancer.
Yeo SG; Kim DY; Park JW; Choi HS; Oh JH; Kim SY; Chang HJ; Kim TH; Sohn DK
Int J Radiat Oncol Biol Phys; 2012 Feb; 82(2):856-62. PubMed ID: 21300482
[TBL] [Abstract][Full Text] [Related]
53. Sequential short-course radiation therapy and chemotherapy in the neoadjuvant treatment of rectal adenocarcinoma.
Jia AY; Narang A; Safar B; Zaheer A; Murphy A; Azad NS; Gearhart S; Fang S; Efron J; Warczynski T; Hacker-Prietz A; Meyer J
Radiat Oncol; 2019 Aug; 14(1):147. PubMed ID: 31426827
[TBL] [Abstract][Full Text] [Related]
54. Local excision in rectal cancer patients with major or complete clinical response after neoadjuvant therapy: a case-matched study.
Bushati M; Pucciarelli S; Gennaro N; Maretto I; Toppan P; Perin A; Urso EDL; Bagatella A; Spolverato G
Int J Colorectal Dis; 2019 Dec; 34(12):2129-2136. PubMed ID: 31724079
[TBL] [Abstract][Full Text] [Related]
55. Lymphovascular invasion is a significant prognosticator in rectal cancer patients who receive preoperative chemoradiotherapy followed by total mesorectal excision.
Lee JH; Jang HS; Kim JG; Cho HM; Shim BY; Oh ST; Yoon SC; Kim YS; Choi BO; Kim SH
Ann Surg Oncol; 2012 Apr; 19(4):1213-21. PubMed ID: 21935746
[TBL] [Abstract][Full Text] [Related]
56. Efficacy and Safety of Two Neoadjuvant Strategies With Bevacizumab in MRI-Defined Locally Advanced T3 Resectable Rectal Cancer: Final Results of a Randomized, Noncomparative Phase 2 INOVA Study.
Borg C; Mantion G; Boudghène F; Mornex F; Ghiringhelli F; Adenis A; Azria D; Balosso J; Ben Abdelghani M; Bachet JB; Vendrely V; François Y; Conroy T; Rio E; Roullet B; Spaëth D; Quero L; Lakkis Z; Coudert M; Ionescu-Goga M; Tanang A; André T
Clin Colorectal Cancer; 2019 Sep; 18(3):200-208.e1. PubMed ID: 31311761
[TBL] [Abstract][Full Text] [Related]
57. The prognostic impact of preoperative blood monocyte count in pathological T3N0M0 rectal cancer without neoadjuvant chemoradiotherapy.
Zhang LN; Xiao W; OuYang PY; You K; Zeng ZF; Ding PR; Pan ZZ; Xu RH; Gao YH
Tumour Biol; 2015 Sep; 36(10):8213-9. PubMed ID: 25994571
[TBL] [Abstract][Full Text] [Related]
58. Comparative Outcomes of Neoadjuvant Treatment Prior to Total Mesorectal Excision and Total Mesorectal Excision Alone in Selected Stage II/III Low and Mid Rectal Cancer.
Kulu Y; Tarantino I; Billeter AT; Diener MK; Schmidt T; Büchler MW; Ulrich A
Ann Surg Oncol; 2016 Jan; 23(1):106-13. PubMed ID: 26305025
[TBL] [Abstract][Full Text] [Related]
59. Korean Society of Coloproctology (KSCP) trial of cONsolidation Chemotherapy for Locally advanced mid or low rectal cancer after neoadjUvant concurrent chemoraDiothErapy: a multicenter, randomized controlled trial (KONCLUDE).
Kim CW; Kang BM; Kim IY; Kim JY; Park SJ; Park WC; Bae KB; Bae BN; Baek SK; Baik SH; Son GM; Lee YS; Lee SH
BMC Cancer; 2018 May; 18(1):538. PubMed ID: 29739356
[TBL] [Abstract][Full Text] [Related]
60. The Time Between Chemoradiation and Surgery for Rectal Carcinoma Negatively Influences Mesorectal Excision Quality.
Sirák I; Pohanková D; Ferko A; Hovorková E; Rozkoš T; Vošmik M; Hodek M; Paluska P; Buka D; Grepl J; Petera J
Pathol Oncol Res; 2020 Jul; 26(3):1565-1572. PubMed ID: 31482400
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
